Efficacy of ultra-low volume (≤1 L) bowel preparation fluids: Systematic review and meta-analysis

Milou L. M. van Riswijk, Kelly E. van Keulen and Peter D. Siersema

Department of Gastroenterology and Hepatology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands

Background and Aims: High-quality bowel preparation is paramount for the diagnostic accuracy and safety of colonoscopy; however, it is often difficult for patients to adhere to high-volume laxatives, which may contribute to poor bowel preparation. This review aims to assess the efficacy of bowel preparation fluids of 1 L or less (≤1 L).

Methods: We performed a systematic review including all relevant randomized controlled trials on ultra-low volume (≤1 L) bowel preparation fluids for colonoscopy published since 2015. Primary endpoint was the percentage of adequately prepared patients. Secondary endpoints included adenoma detection rate (ADR) and safety.

Results: Bowel preparation with sodium picosulfate/magnesium citrate (SPMC; 19 trials, n = 10,287), 1L-polyethylene glycol with ascorbate (PEGA; 10 trials, n = 1717), sodium phosphate (NaP; 2 trials, n = 621), and oral sulfate solution (OSS; 3 trials, n = 597) was adequate in 75.2%, 82.9%, 81.9%, and 92.1%, respectively, of patients; however, heterogeneity between studies was considerable (I² range: 86–98%). Pooled ADRs were 31.1% with SPMC, 32.3% with 1L-PEGA, 30.4% with NaP, and 40.9% with OSS. Temporary electrolyte changes were seen with all ultra-low volume bowel preparation fluid solutions but without sustained effects in most patients.

Conclusion: Ultra-low volume bowel preparation fluids do not always meet the 90% quality standard for adequate bowel preparation as defined by current guidelines. Nonetheless, they may be considered in patients intolerant for higher-volume laxatives and without risk factors for inadequate bowel preparation or dehydration-related complications.

Key words: cathartics, colonoscopy, endoscopy, laxatives, meta-analysis

INTRODUCTION

Colonoscopy is considered the gold standard for screening and surveillance of colorectal cancer (CRC) and its precursor lesions. However, diagnostic accuracy and safety of colonoscopy highly depend on the quality of preprocedural bowel preparation. Inadequate bowel preparation has been reported as frequent as 25% and is associated with a lower adenoma detection rate (ADR), lower procedure completion rate, longer procedure time, higher complication rate, and a higher need for repeat colonoscopy with associated increased healthcare costs.1-7 In light of this, the European Society of Gastrointestinal Endoscopy (ESGE) guidelines advise that at least 90% of the colonoscopy patients should have adequate bowel preparation.1,8

Inadequate bowel preparation is often linked to the high volume of laxatives patients need to drink.9,10 Moreover, the high burden of bowel preparation may be one of the reasons for patients not to undergo colonoscopy.11,12 In the past few years, several strategies have been developed to ensure adequate bowel cleansing, aiming to improve bowel preparation tolerability while maintaining an adequate cleansing effect. The reference standard for bowel preparation consisted for a long time of 3–4 L of polyethylene glycol (PEG) electrolyte solution, due to its efficacy and favorable safety profile.13 More recent randomized clinical trials (RCT) and meta-analyses comparing lower volumes (2 L) of bowel preparation solutions to standard regimes, demonstrated that the former benefit patient compliance and show a higher willingness to repeat colonoscopy while still leading to a high bowel cleansing efficacy.14-16

Nonetheless, even 2 L of poorly tasting laxatives is still less optimal for a subgroup of patients.9,17 In an effort to further optimize patient experience and compliance, several ultra-low volume bowel preparation fluids of 1 L or less have been developed, based on either hypotonic solutions or stimulant laxatives (Appendix S1). In a recently

© 2021 The Authors. Digestive Endoscopy published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
published observational study including 5000 patients, a 300 mL bowel preparation solution consisting of sodium picosulfate with magnesium citrate (SPMC) demonstrated a high willingness to repeat colonoscopy (93.5%) when compared to 4 L PEG (69.4%) and 2 L PEG with ascorbate (73.2%).

The ESGE recommends both high-volume (>2 L) as well as low- (≤2 L), or ultralow-volume (≤1 L) laxatives in healthy patients, based on a non-inferiority outcome of individual studies. However, not all included studies investigating ultralow-volume laxatives were found to meet the quality standard of a minimum of 90% adequate bowel preparation. Considering that the cleansing efficacy is even more important than tolerability, the scope of this review is to assess the efficacy and safety of ultra-low volume fluids (≤1 L) to achieve adequate bowel preparation for colonoscopy.

MATERIALS AND METHODS

Protocol and registration

The protocol was designed in line with the PRISMA guidelines and registered in the PROSPERO database of systematic reviews (CRD42020181630).

Information sources and search strategy

The search was systematically performed on 17 April 2020 in three databases: PubMed, Embase (Ovid interface), and the Cochrane Library (CENTRAL). The search strategy and search terms were developed in collaboration with a medical librarian. Search terms included “colonoscopy”, “laxatives”, “cathartics”, “purgatives”, “bowel evacuant”, “bowel preparation”, “bowel cleansing”, “bowel cleansing”, “visualisation”, “lavage”. Alternative spelling was accounted for. The full search strategy is available in Appendix S2.

Eligibility criteria

We included RCTs that investigated bowel preparation fluids with a volume of ≤1 L, published between 1 January 2015 and 17 April 2020. We excluded studies that did not report original data, animal studies, studies focusing on a specific study population, and conference abstracts. The search was limited to articles either in English or Dutch, with full-text available through the university library or open access publishing.

Study selection

To remove duplicate records, we used Endnote X9.2 (Clarivate Analytics, Philadelphia, PA, USA), after which all remaining records were transported to the web-based screening program Rayyan QCRI. Eligible studies were identified by one researcher (MvR). Uncertainties were resolved through discussion with the senior author (PS).

Outcome measures

Our primary endpoint was the proportion of adequately prepared patients on an intention-to-treat basis. Adequate bowel cleansing was defined as a Boston Bowel Preparation Score (BBPS) score ≥6, Aronchick Scale (AS) score ≥2 (good or excellent), Ottawa Bowel Preparation Scale (OBPS) score ≤5, and Harefield cleansing scale (HCS) grade A or B.

If the outcome was reported with more than one preparation scale, BBPS and OBPS were preferred over AS, as previous studies have shown better interobserver consistency with a Cohen’s kappa coefficient of 0.77, 0.94, and 0.77 for BBPS, OBPS, and AS, respectively. Furthermore, AS is preferred over HCS (kappa 0.457). Additionally, BBPS was preferred over OBPS because of more extensive validation and more frequent use in clinical practice.

Secondary endpoints included ADR and safety. If the primary outcome was not reported, the study was not included in the meta-analysis for efficacy, but only in the safety analysis.

Statistical analysis

We used a random-effects model to calculate the pooled proportion of adequately prepped patients and ADR per type of fluid, using the restricted maximum likelihood method. A Freeman-Tukey double arcsine transformation was used to minimize the effect of extreme proportions (near 1 or 0) in study subsets with small sample sizes and to stabilize variances. Additionally, subgroup analyses and meta-regression on predefined subgroups were conducted. We assessed the effects of the use of additives (i.e. adjunctive laxatives drugs prescribed besides the main laxative, e.g. bisacodyl), the dosing protocol (split-dose, same day, or day before), and diet (liquid diet, low-residue diet, or a combination).

Heterogeneity across the pooled studies was assessed using $I^2$ statistics, with low, moderate, and substantial heterogeneity defined as 25%, 50%, and 75%, respectively. To further explore heterogeneity and to detect possible outliers, influence analyses were conducted, including leave-one-out sensitivity analyses and Baujat-plots. If more than 10 studies were available, a graphic display of study heterogeneity (GOSH plot) analysis was conducted. All analyses were conducted in R3.6.2, using the packages meta, metafor, and dmetar.
Risk of bias assessment

To assess and visualize risk of bias in the included studies, the Cochrane Collaboration Risk of Bias 2 (RoB2) tool was used for randomized interventional trials. Selection bias was assessed using funnel plots.

RESULTS

Search results

Our systematic literature search yielded 5097 citations. After removing duplicates, 3029 were screened based on title and abstract. Based on potential relevance, 239 full-text articles were screened, of which 43 were included. The full selection process is shown in the PRISMA flowchart (Fig. 1).

Study characteristics

Of the 43 included studies, 26 evaluated SPMC, 12 1L-PEG with ascorbate (PEGA), four oral sulfate solution (OSS), four sodium phosphate solution (NaP), two sennosides, and one magnesium citrate (Table 1).

All studies were single- or multicenter assessor-blinded RCTs. Fourteen studies (32%) were sponsored by pharmaceutical companies. Study populations included outpatient patients with various indications for colonoscopy, i.e., screening, surveillance, and diagnostic. Exclusion criteria were commonly accepted contraindications for colonoscopy and contraindications for bowel preparation in general.

Adequately prepared patients per fluid

For SPMC, the percentage of adequately cleaned patients was reported in 19 studies comprising 10,287 patients, with a pooled percentage of 75.2% (95% confidence interval [CI] 67.6–81.4; $I^2 = 96%$; Fig. 2). The pooled estimate was significantly higher in studies that used additives, such as bisacodyl ($n = 9714$), compared to studies that only used the standard dosage of 300 mL SPMC ($n = 573$; $P < 0.01$; Table 2, Fig. S1). Dosing subgroups (same-day, day before, split-dose) performed significantly different in subgroup

Figure 1 PRISMA flow diagram of study selection. RCT, randomized controlled trial.
| Author (year) | Country       | Study design          | Reason for colonoscopy                    | Sample size (ITT) | Age (mean, years) | Intervention (low-volume)                                                                 | Comparison (high-volume) | Additional fluid intake |
|--------------|---------------|-----------------------|------------------------------------------|-------------------|-------------------|--------------------------------------------------------------------------------------------|--------------------------|------------------------|
| Choi 2016‡   | Korea         | SC, SB RCT            | Diagnostic, therapeutic                   | 1. 102            | 1. 49.9           | 1. Split 400 mL SPMC (Picolight) + 10 mg bisacodyl                                            | 2. Split 2 L PEGA (Coolprep) + 20 mL simethicone | 1. 2 L                 |
|              |               |                       |                                          | 2. 98             | 2. 51.6           | 2. Split 2 L PEGA (Coolprep) + 20 mL simethicone                                            |                          | 2. 1.5 L               |
| Dwyer 2017‡  | Australia     | SC non-inferiority RCT| Clinically accepted indications          | 1. 112            | 54 full study     | 1. Split 300 mL SPMC (Picosalax), white diet                                                  | 2. 1 L PEG (Glycoprep-C) + split 300 mL SPMC (Picoprep), LQD | 1. 0.2 L/h             |
|              |               |                       |                                          | 2. 118            |                   | 2. Split 4 L PEG                                                                           |                          | 2. 0.2 L/h             |
| Gweon 2015   | Korea         | SC, SB, non-inferiority RCT | Various                              | 1. 104            | 1. 47.7           | 1. 1.5 SD split 300 mL SPMC + 10 mg bisacodyl (no product names reported)                    | 2. 2 L                  | Extra fluids encouraged |
|              |               |                       |                                          | 2. 105            | 2. 50.6           | 2. Split 4 L PEG                                                                           |                          |                        |
| Heetun 2016  | Ireland       | SC RCT                | Diagnostic, screening, surveillance      | 1. 102            | 1. 56.4           | 1. Split 300 mL SPMC, LQD 3 days                                                            | 2. 4 L PEG, LQD (no product names reported) | Extra fluids encouraged |
|              |               |                       |                                          | 2. 107            | 2. 58.7           | 2. 2.4 L NaP split/DB in morning procedures, LQD                                             |                          |                        |
|              |               |                       |                                          | 3. 122            | 3. 56.8           | 3. 3.24 L NaP split/DB in morning procedures, LQD                                             |                          |                        |
| Hookey 2019‡ | Canada        | MC, SB, non-inferiority RCT | Elective                                      | 1. 448            | 57.2 full study   | 1. Split 320 mL SPMC solution (Clenpiq), LQD                                                  | 1. 2 L                  |                        |
|              |               |                       |                                          | 2. 453            |                   | 2. Split 300 mL SPMC powder (Prepopik), LQD                                                     | 2. 2 L                  |                        |
| Hung 2020    | Taiwan        | MC, SB, non-inferiority RCT | Elective                                      | 1. 316            | 1. 47.7           | 1. Split 300 mL SPMC (Bowclean), LRD                                                          | 2. Split 2 L PEG (Kleanprep) + 5 mg bisacodyl, LRD | 1. 2 L                 |
|              |               |                       |                                          | 2. 315            | 2. 49.4           | 2. Split 4 L PEG                                                                           |                          | 2. None                |
| Jun 2017‡    | Korea         | SC, SB RCT            | Screening, diagnostic                     | 1. 99             | 1. 54.6           | 1. Split 450 mL SPMC (Picolight), LRD 3 days                                                  | 1. 2.5 L                |                        |
|              |               |                       |                                          | 2. 105            | 2. 54.3           | 2. Split 450 mL SPMC (Picolight) with flexible timing of second dose, LRD 3 days           | 2. 2.5 L                |                        |
| Kiesslich 2017‡ | Germany    | MC, SB RCT            | Elective                                | 1. 131            | 1. 58.3           | 1. Split 300 mL SPMC (Picoprep)                                                             | 1. 2 L                  |                        |
|              |               |                       |                                          | 2. 73             | 2. 56.6           | 2. Split 300 mL SPMC (Picoprep)                                                             | 2. 2 L                  |                        |
| Kim 2015     | Korea         | MC, SB, non-inferiority RCT | Screening, diagnostic, treatment         | 1. 153            | 1. 53.5           | 1. Split 300 mL SPMC (Picolight) + 10 mg bisacodyl, LRD                                     | 2. Split 4 L PEG, 3 days |                        |
|              |               |                       |                                          | 2. 166            | 2. 53.8           | 2. Split 4 L PEG                                                                           |                          | 2. None                |
Table 1 (Continued)

| Author (year) | Country          | Study design | Reason for colonoscopy | Sample size (ITT) | Age (mean, years) | Intervention (low-volume) | Comparison (high-volume) | Additional fluid intake |
|---------------|------------------|--------------|------------------------|-------------------|-------------------|--------------------------|--------------------------|------------------------|
| Kim 2016      | Korea            | SC, SB RCT   | Diagnostic             | 1. 59             | 1. 54             | 1. DB SPMC (Picolight) + NaP (Clicolon) + 10 mg bisacodyl, 1 day LRD | 3. DB SPMC (Picolight) + 1L-PEGA (Coolprep) + 10 mg bisacodyl, 1 day LRD | 1. 1 L                  |
|               |                  |              |                        | 2. 58             | 2. 53             | 2. Split SPMC (Picolight) + NaP (Clicolon) + 10 mg bisacodyl, 1 day LRD | 4. Split SPMC (Picolight) + 1L-PEGA (Coolprep) + 10 mg bisacodyl, 1 day LRD | 2. 1 L                  |
|               |                  |              |                        | 3. 57             | 3. 53             | 3. DB SPMC (Picolight) + 1L-PEGA (Coolprep) + 10 mg bisacodyl, 1 day LRD | 5. DB 2L PEG (Moviprep), LRD 3 days | 3. 1.5 L                |
|               |                  |              |                        | 4. 55             | 4. 55             | 4. Split SPMC (Picolight) + 1L-PEGA (Coolprep) + 10 mg bisacodyl, 1 day LRD | 6. Split 3/1 L PEG (Fortrans), LRD 3 days | 4. 1.5 L                |
| Kim 2020      | Korea            | SC, SB RCT   | Screening, surveillance, diagnostic, treatment | 1. 97             | 1. 56.5           | 1. Split 340 mL SPMC (Picosolution) + 10 mg bisacodyl, LRD 3 days | 3. Split 2 L PEGA (Coolprep), LRD 3 days | 1. 2 L                  |
|               |                  |              |                        | 2. 99             | 2. 54.4           | 2. 5 L PEGA (Coolprep), LRD 3 days | 4. Split 3/1 L PEG (Moviprep), LRD 3 days | 2. 1 L                  |
|               |                  |              |                        | 3. 99             | 3. 58.1           | 3. 5 L PEGA (Coolprep), LRD 3 days | 5. Split 2 L PEGA (Forte trans), LRD 3 days | 3. 1 L                  |
| Klare 2015    | Germany          | SC, SB RCT   | NR                     | 1. 99             | 1. 53.4           | 1. DB 300 mL SPMC (Picoprep), 1 day LQD | 2. Split 4–6 L PEG (Oralav; until clear stool), 1 day LQD | 1. 250 mL/h |
|               |                  |              |                        | 2. 101            | 2. 56.4           | 2. DB 300 mL SPMC (Picoprep), 3 days LRD | 3. DB 2L-PEGA (Moviprep), 3 days LRD | 1 + 2. 2 L |
|               |                  |              |                        | 973†              | NR                | 3. DB 300 mL SPMC (Picoprep), 3 days LRD | 4. Split 2 L PEGA (Moviprep), 3 days LRD | 3–6. None               |
| Kojeccky 2017 | Czech Republic   | MC, SB RCT   | NR                     | 178               | 1. 60.2           | 1. DB 300 mL SPMC (Picoprep), LRD 3 days | 3. DB 2 L PEGA (Moviprep), LRD 3 days | 1 + 2. 2 L |
|               |                  |              |                        | 3 + 4.            | 3 + 4.            | 2. Split 300 mL SPMC (Picoprep), LRD 3 days | 4. Split 2 L PEGA (Moviprep), LRD 3 days | 3 + 4. 1.5 L |
|               |                  |              |                        | 189               | 60.5             | 5. DB 4 L PEG (Fortrans), LRD 3 days | 5. DB 4 L PEG (Fortrans), LRD 3 days | 5 + 6. None               |
|               |                  |              |                        | 5 + 6.            | 5 + 6.            | 6. Split 3/1 L PEG (Fortrans), LRD 3 days | 6. Split 4 L PEG (Fortrans), LRD 3 days | None                |
| Kojeccky 2018 | Czech Republic   | MC, SB RCT   | NR                     | 1 + 2.            | 1 + 2.            | 1. DB 300 mL SPMC (Picoprep), LRD 3 days | 3. DB 2 L PEGA (Moviprep), LRD 3 days | 1 + 2. 2 L |
|               |                  |              |                        | 178               | 60.2             | 2. Split 300 mL SPMC (Picoprep), LRD 3 days | 4. Split 2 L PEGA (Moviprep), LRD 3 days | 3 + 4. 1.5 L |
|               |                  |              |                        | 3 + 4.            | 3 + 4.            | 3. DB 2 L PEGA (Moviprep), LRD 3 days | 5. DB 4 L PEG (Fortrans), LRD 3 days | 5 + 6. None               |
| Munsterman    | The Netherlands  | SC, SB RCT   | Surveillance, diagnostic, treatment | 1. 85             | 1. 57            | 1. Split 300 mL SPMC (Picoprep), LRD 2 days, LQD 1 day | 2. Split 3/1 L PEG (Kleanprep), LRD 2 days, LQD 1 day | 1. 4 L                  |
| 2015          |                  |              |                        | 2. 88             | 2. 55            | 2. Split 300 mL SPMC (Picoprep), LRD 2 days, LQD 1 day | 3. DB 4 L PEG, LRD 2 days prior, LQD 1 day | 2. unspeci- fied |
| Muñoz-Navas   | Spain            | SC, SB RCT   | First-time diagnostic endoscopy | 1. 224            | 1. 50.7          | 1. DB SPMC, LRD 2 days prior, LQD 1 day | 2. DB 4 L PEG, LRD 2 days prior, LQD 1 day | 1. 250 mL/h |
| 2015†         |                  |              |                        | 2. 213            | 2. 53.6          | 2. Split 300 mL SPMC, LRD 2 days prior, LQD 1 day | 3. DB 4 L PEG, LRD 2 days prior, LQD 1 day | 2. 250 mL/h |
|               |                  |              |                        | 3. 53             | 3. 55.3          | 3. Split 300 mL SPMC, LRD 2 days prior, LQD 1 day | 4. Split 3/1 L PEG (Fortrans), LRD 3 days | 3. None |

© 2021 The Authors. Digestive Endoscopy published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.
| Author (year) | Country          | Study design          | Reason for colonoscopy                | Sample size (ITT) | Age (mean, years) | Intervention (low-volume)                                                                 | Comparison (high-volume)                                      | Additional fluid intake |
|--------------|------------------|-----------------------|--------------------------------------|-------------------|------------------|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------|------------------------|
| Pisera 2019  | Poland           | MC, SB RCT            | Screening                            | 1. 6752           | 55-62            | 1. Mixed DB/split 300 mL SPMC (Citrafleet), 1 day LRD, 0.5 day LQD                           | 2. Mixed DB/split 4 L PEG (Fortrans), 1 day LRD, 0.5 day LQD    | 1. 4 L                 |
|              |                  |                       |                                      | 2. 6745           |                   | 2. Mixed DB/split 4 L PEG (Fortrans), 1 day LRD, 0.5 day LQD                           |                                                                | 2. None                |
| Pohl 2015‡  | Germany          | MC, SB RCT            | Diagnostic, screening, surveillance  | 1. 193            | 1. 60.1          | 1. DB 300 mL SPMC (Citrafleet), LRD 1 day, 0.5 day LQD                                   | 2. Split 2 L PEGA (Moviprep), LRD 1 day, 0.5 day LQD            | 1. 250 mL/h            |
|             |                  |                       |                                      | 2. 200            | 2. 59.5          | 2. Mixed DB/split 300 mL SPMC (Citrafleet), LRD 1 day, 0.5 day LQD                    |                                                                | 2. 1 L                 |
| Prieto-Frias 2016 | Spain          | MC stratified trial   | Elective outpatient                  | 1. 157            | 1. 53.7          | 1. Split SPMC (Citrafleet), LRD 2 days                                                  |                                                                | NR                     |
|              |                  |                       |                                      | 2. 148            | 2. 55.7          | 2. DB 300 mL SPMC (Citrafleet), LRD 2 days                                                |                                                                |                        |
| Rostom 2019  | Canada           | SC RCT                | Screening, surveillance              | 1. 33             | 1. 57.6          | 1. DB SPMC, LRD 4 days, LQD 1 day                                                       | 3. DB 2 L PEG, LRD 4 days, LQD 1 day                           | NR                     |
|             |                  |                       |                                      | 2. 28             | 2. 56.4          | 2. Split SPMC, LRD 4 days, LQD 1 day                                                     | 4. Split 2 L PEG, LRD 4 days, LQD 1 day                         |                        |
|             |                  |                       |                                      | 3. 34             | 1. 57.2          | 3. DB 300 mL SPMC (Picolax), LQD 0.5 day                                                 | 2. DB 2 L PEG (Moviprep), LQD 0.5 day                         | 1. 2 L                 |
|             |                  |                       |                                      | 4. 36             | 2. 59.3          | 4. Split 2 L PEG, LRD 4 days, LQD 1 day (no product names reported)                     |                                                                | 2. 2 L                 |
| Sahebally 2015 | Ireland        | SC, SB RCT            | NR                                   | 1. 64             | 1. 57.2          | 1. DB 300 mL SPMC (Picolax), LQD 0.5 day                                                 | 2. DB 2 L PEG (Moviprep), LQD 0.5 day                         | 1. 2 L                 |
|             |                  |                       |                                      | 2. 66             | 2. 59.3          | 2. DB 300 mL SPMC (Picolax), LQD 0.5 day                                                 |                                                                | 2. 2 L                 |
| Schulz 2016‡ | Germany          | MC, SB RCT            | Screening, surveillance, diagnostic, IBD | 1. 156            | 57.1             | 1. DB 300 mL SPMC, LRD 1 day, LQD starting preparation                                   | 1 + 2. 250 mL/h                                               |                        |
|             |                  |                       |                                      | 2. 159            | (full study)     | 2. Split 300 mL SPMC, LRD 1 day, LQD starting preparation                                |                                                                |                        |
| Seo 2018    | Korea            | SC, SB RCT            | Elective outpatient colonoscopy, screening, surveillance, diagnostic | 1. 114            | 1. 54.9          | 1. Split 300/150 mL SPMC (Picolight), LRD 3 days, LQD 1 day                            | 2. Split 2 L PEG (Coolprep), LRD 3 days, LQD 1 day              | 1. 2 L                 |
|             |                  |                       |                                      | 2. 109            | 2. 56.1          | 2. Split 300 mL SPMC (Picolight), LRD 3 days, LQD 1 day                                |                                                                | 2. 1 L                 |
| Voiosu 2017 | Romania          | MC, SB RCT            | Outpatient, first colonoscopy, screening, surveillance, diagnostic | 1. 37             | 1. 58            | 1. Split 300 mL SPMC (Picolight), 1 day LRD 3 days, LQD starting preparation           | 2. Split 4 L PEG (Fortrans), 1 day LRD                         | 1. 250 mL/h            |
|             |                  |                       |                                      | 2. 37             | 2. 57            | 2. Split 4 L PEG (Fortrans), 1 day LRD 3 days, LQD starting preparation                |                                                                | 2. None                |
|             |                  |                       |                                      | 3. 69             | 3. 54            | 3. Individualized SPMC or PEG based on questionnaire                                    | 3b. Individualized SPMC or PEG based on questionnaire           |                        |
|             |                  |                       |                                      | 34/35             |                 |                                                                                         |                                                                |                        |
| Yoo 2015    | Korea            | SC, SB RCT            | Screening, surveillance, diagnostic  | 1. 100            | 1. 53.3          | 1. Split 300 mL SPMC (Picolight), LRD 3 days, LQD starting preparation                | 2. Split 2 L PEG (Coolprep), LRD 3 days, LQD starting preparation | 1. 2 L                 |
|             |                  |                       |                                      | 2. 100            | 2. 57.0          | 2. Split 2 L PEG (Coolprep), LRD 3 days, LQD starting preparation                    |                                                                | 2. 1 L                 |
| Author (year) | Country | Study design | Reason for colonoscopy | Sample size (ITT) | Age (mean, years) | Intervention (low-volume) | Comparison (high-volume) | Additional fluid intake |
|---------------|---------|--------------|------------------------|------------------|------------------|-------------------------|--------------------------|-------------------------|
| Schreiber 2019‡ Germany | MC, SB, non-inferiority RCT | Screening, surveillance, diagnostic | 1. 251 2. 250 | 1. 52.9 2. 54.6 | 1. DB 300 mL SPMC (Citrafleet), LQD 0.5 day 2. DB 1L-PEGA (NER1006, Plenvu), LQD 0.5 day | 3. Split 2 L PEGA (Moviprep), 1 day LRD, 0.5 day LQD | 1. 250 mL/h 2. 1 L |
| Bisschops 2019‡ Belgium | MC, SB, non-inferiority RCT | Screening, surveillance, diagnostic | 1. 275 2. 275 3. 272 | 1. 56.3 2. 54.9 3. 54.3 | 1. Split 1L-PEGA (NER1006, Plenvu), 1 day LRD, 0.5 day LQD 2. SD 1L-PEGA (NER1006, Plenvu), 1 day LRD, 0.5 day LQD | 3. Split 2 L PEGA (Moviprep), 1 day LRD, 0.5 day LQD | Ad libitum |
| DeMicco 2019‡ USA | MC, SB, non-inferiority RCT | Out/inpatient, screening, surveillance, diagnostic | 1. 276 2. 280 | 1. 57.5 2. 56.8 | 1. Split 1L-PEGA (NER1006, Plenvu), 1 day LRD, 0.5 day LQD 2. Split 1 L OSS (Suprep), 1 day LRD, 0.5 days LQD | | 1. 1 L 2. 2 L |
| Choi 2018 Korea | SC, SB, non-inferiority RCT | Elective outpatient, screening, surveillance, diagnostic | 1. 130 2. 130 | 1. 55.3 2. 58.5 | 1. Split 1 L PEGA (Coolprep) + 2 mg prucalopride, LRD 3 days prior | 2. Split 2 L PEGA (Coolprep), LRD 3 days prior | 1. 1 L 2. 1 L |
| Kamei 2018 Japan | SC, non-inferiority trial | Outpatient, screening, surveillance, IBD | 1. 68 2. 44 | 45.5 (full study) | 1. SD 1 L PEGA (Moviprep) + DB 5 mg mosapride citrate hydrate AC, 24 mg sennoside AN | 2. SD 2 L PEG (NIFLEC) + DB 5 mg mosapride citrate hydrate AC, 24 mg sennoside AN | 1. 0.5 L 2. None |
| Kang 2017 Korea | SC, SB RCT | Screening, surveillance, diagnostic, previous abdominal surgery | 1. 100 2. 100 | 1. 54.4 2. 56.8 | 1. SD 1L-PEGA (Coolprep) + 10 mg bisacodyl evening before, LRD 3 days prior | 2. Split 2 L PEGA (Coolprep), LRD 3 days prior | 1. 1.5 L 2. 1 L |
| Kim 2019 Korea | SC, SB RCT | Screening, surveillance, diagnostic | 1. 83 2. 85 | 1. 52.3 2. 56.8 | 1. SD 1 L PEGA (Clicool) + 20 mg bisacodyl, clear LQD evening prior | 2. Split 2 L PEGA (Clicool), clear LQD evening prior | 1. 1 L 2. 1 L |
| Kwon 2016‡ Korea | MC, SB, non-inferiority RCT | Elective | 1. 91 2. 96 | 1. 59.6 2. 56.0 | 1. SD 1 L PEGA, evening prior 20 mg bisacodyl, LRD 3 days prior | 2. Split 2 L PEGA, LRD 3 days prior (no product names reported) | 1. 1 L 2. 1 L |
| Author (year) | Country | Study Design | Reason for Colonoscopy | Sample Size (ITT) | Age (mean, years) | Intervention (low-volume) | Comparison (high-volume) | Additional Fluid Intake |
|--------------|---------|--------------|------------------------|-------------------|------------------|--------------------------|-------------------------|-------------------------|
| Banerjee 2016 | India | SC, double-blind non-inferiority trial | Diagnostic, IBD, surveillance | 1. 71, 2. 75, 3. 221, 4. 221 | 45.8 (full study) | 1. SD 1 L PEG (Peglec) + 24 mcg lubiprostone, clear LQD starting preparation | 2. SD 1.5 L PEG (Peglec) + lubiprostone | NR |
| Tian 2019 | China | SC, SB RCT | Diagnostic, surveillance | 1. 82, 2. 84, 3. 80 | 1. 52.3, 2. 52.3, 3. 49.0 | 1. Split 1L-PEG + 30 mL castor oil + 20 mL simethicone, LRD 3 days (no product names reported) | 2. Split 2 L PEG + 30 mL castor oil + 20 mL simethicone | 3. None |
| Poyrazoglu 2015 | Turkey | SC, SB RCT | Elective-screening, surveillance, diagnostic, IBD | 1. 66, 2. 62 | 1. 47.7, 2. 49.8 | 1. Split 90 mL NaP, 3 days prior LRD, 1 day LQD | 2. Split 500 mL 1000 mg Sennosides A and B calcium + 66.6 g sorbitol | NR |
| Hung 2019 | China | SC RCT | NR | 1. 93, 2. 97 | 1. 49.7, 2. 48.9 | 1. Split 90 mL NaP (Fleet Phospho-soda), LRD 2 days, 0.5 day LQD | 2. SD 45 mL NaP (Fleet Phospho-soda), 2 mg prucalopride 8 pm DB, LRD 2 days, 0.5 day LQD | 1. 1.5 L, 2. 1.5 L |
| Kang 2015 | Taiwan | SC, non-concurrent control group RCT | Screening | 1. 259, 2. 172 | 1. 47.7, 2. 47.8 | 1. DB 90 mL NaP (Fleet Phospho-soda) | 2. Split 90 mL NaP (Fleet Phospho-soda) | NR |
| Yang 2020‡ | Korea | MC, SB, non-inferiority RCT | Diagnostic, screening, surveillance | 1. 112, 2. 112 | 1. 48.2, 2. 46.4 | 1. Split 946 mL OSS (Suprep), 1 day LQD | 2. DB 14 NaP tablets (PBK-1701TC, Pharmbio) + 2.5 L water, 1 day LQD | 1. 2 L, 2. 2.5 L |
| Lee 2019‡ | Korea | SC, SB, non-inferiority RCT | Diagnostic, screening, surveillance, therapy | 1. 93, 2. 94 | 60.2 (full study) | 1. Split 946 mL OSS (Suclear), LRD 3 days prior | 2. Split 2 L PEGA (Coolprep), LRD 3 days prior | 1. 2 L, 2. 1 L |
| Gerard 2017 | USA | SC, SB RCT | Elective, screening, surveillance, diagnostic | 1. 200, 2. 200 | 1. 60.6, 2. 60.1 | 1. Split 946 mL OSS (Suprep), 1 day LQD | 2. Split 2 L PEGA (Moviprep), 1 day LQD | 1. 2 L, 2. 1 L |
analysis ($P < 0.00001$), with a negative trend for day-before dosing (Table 2, Fig. S2). Bowel preparation efficacy did not differ significantly between diet subgroups (liquid, low-residue, or combined; Table 2, Fig. S3).

Ten studies comprising 1717 patients reported the proportion of adequately prepared patients using 1L-PEGA, with a pooled percentage of 82.9% (95% CI 74.4–90.1; $I^2 = 94%$; Fig. 3). The pooled efficacy of seven studies ($n = 641$) using additives was comparable to the efficacy of NER1006, a 1L-PEG solution with a higher ascorbate concentration (Table 2, Fig. S4). In addition, subgroup analysis for dosing subgroups showed comparable efficacy of same-day or split dosing (Table 2, Fig. S5). Subgroup analysis for diet effect did not show a significant difference in bowel cleansing efficacy (Table 2, Fig. S6).

Two studies comprising 621 patients reported the efficacy of NaP, with a pooled percentage adequately prepared patients of 81.9% (95% CI 36.7–97.2; $I^2 = 98%$; Fig. 4). For OSS, three studies comprising 597 patients reported on our primary endpoint, with a pooled percentage of 92.1% (95% CI 79.7–97.2; $I^2 = 86%$; Fig. 5). Due to the small number of studies available, no subgroup analyses could be performed.

Furthermore, the two studies investigating the efficacy of sennosides did not report on preparation adequacy in a proportional manner.

**Secondary endpoints**

**Adenoma detection rate**

Adenoma detection rate was reported in 10 SPMC studies with a pooled ADR of 31.0% (95% CI 25.6–36.7; $I^2 = 83%$) and in eight 1L-PEGA studies with a pooled ADR of 32.4% (95% CI 26.6–38.4; $I^2 = 83%$). ADR was reported in one study in the NaP group and was 30.4% (95% CI 20.6–41.2), and in two studies in the OSS group with a pooled ADR of 40.9% (95% CI 28.3–54.2; $I^2 = 81%$; Fig. 6a–d).

**Safety**

All included studies reported gastrointestinal symptoms such as abdominal pain and distention, anal irritation, nausea, and to a lesser extent vomiting as most frequent adverse events (AEs). Furthermore, headache, dizziness, and general malaise were reported with the use of all fluids.

Of the 26 SPMC studies, 22 reported on AEs, and six evaluated laboratory abnormalities. A range of 8.1–85.6% of the patients experienced at least some of the AEs as mentioned above. Moreover, three studies$^{37,39,42}$ reported elevated serum magnesium in 3.6–10.5% of the patients.
and decreased serum sodium levels in up to 21.2% of patients\textsuperscript{45} with one report of severe hyponatremia (119 mmol/L).\textsuperscript{55} Schulz et al. reported hyperkalemia (6.2 and 8.5 mmol/L, respectively) in two young patients, which resolved without sequelae.

In the 1L-PEGA group, AEs were reported in 11 of 12 studies, occurring in 13.2–43.4% of patients. In the NER1006 studies,\textsuperscript{58,60,61} higher rates of temporary decrease in renal function and hypernatremia (median +4.0 mmol/L from baseline) were reported, compared to other ultra-low volume fluids included in these review.

For NaP, AEs were reported in two of the four included studies, occurring in 44.3–72.2% of the patients. The type of reported AEs was similar to those reported above. Additionally, an increase in serum inorganic phosphorus levels (from a median of 3.5 mEq/L at baseline to 6.3 mEq/L at the day of colonoscopy) was noted.\textsuperscript{72}

Adverse events were reported in all OSS studies and occurred over a range of 18.5–77.4% of the patients. Laboratory abnormalities included a temporary decrease in renal function.\textsuperscript{61} Other electrolyte changes were not considered as clinically significant.\textsuperscript{61,69}

### Figure 2

Pooled proportion for adequately prepped patients, sodium picosulfate with magnesium citrate (SPMC). CI, confidence interval.

Heterogeneity

Heterogeneity was considerable for all bowel preparation fluid studies and could only partially be explained by the prespecified subgroups (additive use and differences in dosing schedule). In subgroup analyses based on type of bowel preparation scale, $I^2$ remained substantial (BBPS $I^2$ 91%, OBPS $I^2$ 96%, data not shown). No changes in the pooled effect size nor in the extent of heterogeneity were observed in sensitivity analysis (Fig. S7). Influence analysis, including Baujat and GOSH plots, identified possible outliers\textsuperscript{55,58,68,74} (Figs S7–S9). Excluding these outliers in the meta-analyses did not, however, change the pooled effect sizes significantly but reduced the CI. For SPMC, the CI changed from 67.6–81.4 to 73.2–76.0. For 1L-PEGA,
after removing the outliers, the pooled percentage changed non-significantly from 82.9% (95% CI 74.4–90.1; \(I^2 = 94\%\)) to 77.0% (95% CI 75.7–78.1; \(I^2 = 94\%\)).

### Risk of bias

Funnel plots showed no evidence for publication bias (Fig. S11a–d). The overall risk of bias was low in 58.1%, intermediate in 23.3%, and high in 16.3% of the included studies (Fig. 7, Fig. S12). The pooled outcome did not change significantly for any of the fluids when excluding the studies classified as high risk of bias, but for the 1L-PEGA group, a drop from 83.0% (95% CI 74.4–90.1) to 75.3% (95% CI 73.0–77.3) was found.

### DISCUSSION

THIS SYSTEMATIC REVIEW and meta-analysis show that ultra-low volume (≤1 L) bowel preparation with SPMC, 1L-PEGA, NaP, or OSS, was adequate in 75.2%, 82.9%, 81.9%, and 92.1% of patients, respectively. While ESGE guidelines on bowel preparation and CRC screening recommend an adequate bowel cleansing rate in at least 90% of procedures, the majority of these ultra-low volume bowel preparation fluids, with the exception of OSS, do not meet this quality standard as defined by the ESGE in our analysis. It should be noted that only a low number of studies investigating NaP (\(n = 4\)) and OSS (\(n = 4\)) were included, which likely mirrors their limited use in daily clinical practice. The preference for SPMC and 1L-PEGA in various international guidelines is motivated by potential

### Table 2 Subgroup analyses for sodium picosulfate with magnesium citrate and 1 L polyethylene glycol with ascorbate

| Subgroup analysis (category) | No. of studies | Adequately prepared (%) | 95% CI | \(I^2\) (%) |
|-----------------------------|----------------|-------------------------|-------|----------|
| All studies                 | 43             | 75.15 (67.63–81.41)     | 96    |
| SPMC                        | 19             | 82.94 (74.39–90.08)     | 94    |
| 1L-PEGA                     | 10             | 92.06 (79.67–97.17)     | 86    |
| NaP                         | 2              | 81.91 (73.75–79.24)     | 98    |
| OSS                         | 3              | 85.77 (74.05–92.71)     | 96    |
| With additives              | 14             | 86.79 (53.13–97.44)     | NA    |
| Without additives           | 1              | 52.71 (36.52–68.36)     | 91    |
| Same day                    | 6              | 77.96 (68.40–85.25)     | 93    |
| Day before                  | 3              | 78.68 (59.84–90.14)     | 98    |
| Split-dose                  | 9              | 80.42 (66.45–89.50)     | 92    |
| Low-residue diet            | 6              | 69.75 (57.46–79.74)     | 96    |
| Combined                    | 9              | 85.77 (74.05–92.71)     | 96    |

**1L-PEGA, 1 L polyethylene glycol with ascorbate; CI, confidence interval; NA, not applicable; NaP, sodium phosphate solution; OSS, oral sulfate solution; SPMC, sodium picosulfate with magnesium citrate.**

**Figure 3** Pooled efficacy for 1 L polyethylene glycol with ascorbate (PEGA).
Evidence on the efficacy of low-volume fluids is contradictory. Some meta-analyses comparing high-volume (>3 L) PEG with lower-volume fluids (≤2 L) have demonstrated a lower efficacy of low-volume fluids, whereas others have suggested non-inferiority when comparing these two different volume fluids. An explanation of the suboptimal efficacy results in our meta-analysis may well be that we limited our analysis to high- or intermediate volume laxatives such as 4L-PEG or 2L-PEGA, which have a well-established efficacy profile. Therefore, when 2 L preps are included in the same group as the ultra-low-volume fluids, this may improve the overall efficacy results of the low-volume group and give the wrong impression that all low-volume fluids are equally effective or non-inferior to the high-volume counterpart. Another explanation may be that day-before-dosing generally performed worse than split-dose protocols in our analysis. This has also been reported in other meta-analyses and might at least partly explain why the pooled efficacy we found is lower than expected as in the included studies both split-dose and day-before dosing was used. It is recommended that a colonoscopy procedure should take place within 2–5 h after finishing bowel preparation to make sure that the colon is most optimally prepped, thereby reducing the risk that neoplastic lesions will be missed due to bowel contamination. Furthermore, it is questionable whether split dosing is feasible with ultra-low volume fluids, especially in isotonic fluids, or that same-day dosing should be standard. Split dosing may lower the purging effect of the first dose, thereby reducing the final laxative effect of the hypertonic second dose. In our dosing-stratified analyses, the pooled efficacy of same-day and split dosing were close to the recommended 90%. Further studies on ultra-low volume fluids should focus on the efficacy of dosing on the day of colonoscopy, as in this way ultra-low volume bowel preparation fluids might still be a viable option for bowel cleansing.

The ultra-low volume laxatives presented here may offer a solution for patients having difficulties with drinking high volumes. Additionally, the optimized patient perception as compared to high-volume fluids likely will increase the willingness of patients to repeat colonoscopy and decreases the number of patients avoiding colonoscopy. Spadaccini et al. performed a meta-analysis including 17 RCTs (n = 7582) in which they showed that the compliance rate, tolerability, and willingness to repeat taking the same preparation were all in favor of low-volume (<2 L) preparations. Nevertheless, lowering the volume of bowel preparation fluids does not release patients from drinking large volumes.

| Study            | Events | Total | Adequately prepped (%) | 95% CI               | weight |
|------------------|--------|-------|------------------------|----------------------|--------|
| Hung 2019–a      | 89     | 93    | 95.70 [89.10; 98.38]   | 24.3%                |
| Hung 2019–b      | 93     | 97    | 95.88 [89.52; 98.44]   | 24.3%                |
| Kang 2015–a      | 57     | 259   | 22.01 [17.38; 27.46]   | 25.7%                |
| Kang 2015–b      | 133    | 172   | 77.33 [70.47; 82.97]   | 25.6%                |

Figure 4: Pooled efficacy for sodium phosphate solution (NaP). CI, confidence interval.

| Study            | Events | Total | Adequately prepped (%) | 95% CI               | weight |
|------------------|--------|-------|------------------------|----------------------|--------|
| DeMicco 2018–b   | 227    | 280   | 81.07 [76.05; 85.24]   | 28.7%                |
| Lee 2019         | 80     | 93    | 86.02 [77.40; 91.71]   | 27.1%                |
| Yang 2020–a      | 107    | 112   | 95.54 [89.72; 98.13]   | 24.5%                |
| Yang 2020–b      | 110    | 112   | 98.21 [93.14; 99.55]   | 19.7%                |

Figure 5: Pooled efficacy for oral sulfate solution (OSS). CI, confidence interval.
> | Study                        | Events | Total | Adenoma detection rate (%) | 95% CI | weight |
|-----------------------------|--------|-------|-----------------------------|-------|--------|
| Dwyjer 2017                 | 24     | 112   | 21.43 [14.28; 29.55]        | 8.0%  |
| Gweon 2015                  | 41     | 104   | 39.42 [30.21; 49.02]        | 7.9%  |
| Hookey 2019–a               | 130    | 453   | 28.70 [24.62; 32.96]        | 9.4%  |
| Hookey 2019–b               | 141    | 448   | 31.47 [27.25; 35.66]        | 9.4%  |
| Kim MJ 2016–a               | 21     | 58    | 36.21 [24.25; 49.06]        | 6.8%  |
| Kim MJ 2016–b               | 24     | 59    | 40.68 [28.42; 53.54]        | 6.9%  |
| Klare 2015                  | 18     | 99    | 18.18 [11.14; 26.45]        | 7.9%  |
| Pisera 2019                 | 2039   | 6752  | 30.20 [29.11; 31.30]        | 9.9%  |
| Pohl 2015                   | 49     | 193   | 25.39 [19.48; 31.79]        | 8.8%  |
| Schreiber 2019              | 47     | 251   | 18.73 [14.12; 23.80]        | 9.0%  |
| Seo 2018                    | 57     | 114   | 50.00 [40.81; 59.19]        | 8.1%  |
| Yoo 2015                    | 42     | 100   | 42.00 [32.47; 51.84]        | 7.9%  |

Pooled proportion (random effects) 8743 31.05 [25.63; 36.74] 100.0%
Heterogeneity: $I^2 = 83\%$, $\chi^2 = 0.0093$, p < 0.01

> | Study                        | Events | Total | Adenoma detection rate (%) | 95% CI | weight |
|-----------------------------|--------|-------|-----------------------------|-------|--------|
| Bisschops 2019–a            | 73     | 275   | 26.55 [21.48; 31.94]        | 12.3% |
| Bisschops 2019–b            | 76     | 275   | 27.64 [22.50; 33.08]        | 12.3% |
| Choi 2018                   | 59     | 130   | 45.38 [36.89; 54.02]        | 11.0% |
| DeMicco 2018                | 93     | 276   | 33.70 [28.23; 39.39]        | 12.3% |
| Kamei 2018                  | 23     | 68    | 33.82 [23.00; 45.55]        | 9.3%  |
| Kang 2017                   | 45     | 100   | 45.00 [35.33; 54.86]        | 10.4% |
| Kim SH 2020                 | 37     | 99    | 37.37 [28.07; 47.16]        | 10.3% |
| Schreiber 2019              | 47     | 250   | 18.80 [14.18; 23.90]        | 12.2% |
| Tian 2019                   | 24     | 82    | 29.27 [19.87; 39.63]        | 9.8%  |

Pooled proportion (random effects) 1555 32.36 [26.60; 38.40] 100.0%
Heterogeneity: $I^2 = 83\%$, $\chi^2 = 0.0074$, p < 0.01

> | Study                        | Events | Total | Adenoma detection rate (%) | 95% CI | weight |
|-----------------------------|--------|-------|-----------------------------|-------|--------|
| Kang 2015–a                 | 66     | 259   | 25.48 [20.35; 30.98]        | 51.9% |
| Kang 2015–b                 | 62     | 172   | 36.05 [29.02; 43.38]        | 48.1% |

Pooled proportion (random effects) 431 30.44 [20.63; 41.23] 100.0%
Heterogeneity: $I^2 = 82\%$, $\chi^2 = 0.0054$, p = 0.02

> | Study                        | Events | Total | Adenoma detection rate (%) | 95% CI | weight |
|-----------------------------|--------|-------|-----------------------------|-------|--------|
| DeMicco 2018–b              | 98     | 280   | 35.00 [29.51; 40.69]        | 54.8% |
| Lee 2019                    | 45     | 93    | 48.39 [38.25; 58.59]        | 45.2% |

Pooled proportion (random effects) 373 40.94 [28.29; 54.23] 100.0%
Heterogeneity: $I^2 = 81\%$, $\chi^2 = 0.0074$, p = 0.02

Figure 6 Forrest plots for pooled adenoma detection rate for fluid studies. (a) Sodium picosulfate with magnesium citrate (SPMC), (b) 1 L polyethylene glycol with ascorbate (PEGA), (c) sodium phosphate solution (NaP), (d) oral sulfate solution (OSS). CI, confidence interval.

© 2021 The Authors. Digestive Endoscopy published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.
volumes. The stimulant and hyperosmotic pharmacologic mechanism of action that draws water into the gut lumen makes taking extra fluids necessary in addition to the laxatives. Thus, patients should be instructed to maintain hydration to compensate for the large fecal effluent of 2.5 L–3 L. For the 300 mL prep SPMC for example, this means drinking at least 2 L of fluid, which is the same as is recommended in addition to 2L-PEGA.

High-volume bowel preparation fluids such as 4L-PEG may anyhow be preferable in patients with a high risk of dehydration-related complications, such as acute kidney injury, or fluid shifts. The iso-osmotic nature of the PEG electrolyte solution minimizes fluid shifts and thereby reduces the risk of electrolyte disturbances. These electrolyte disturbances such as transient hypermagnesemia for SPMC, hypo- or hypernatremia for 1L-PEGA, and hyperphosphatemia for NaP have been reported in this systematic review, as well as in other publications. No serious AEs were reported in our included studies, but there are case reports that report on fatal hyponatremia and hypermagnesemia. The rare risk of acute phosphate nephropathy caused by tubular calcium depositions due to NaP use has resulted in a warning by the United States Food and Drug Administration to consider alternative bowel preparations instead of NaP. Therefore, hyperosmotic ≤1 L laxatives may be less suitable for elderly or patients with renal dysfunction.

Nonetheless, it is debatable whether the above-mentioned electrolyte changes are clinically relevant for the majority of patients. In a retrospective study of 2.8 million participants, 30- and 90-day hospitalizations for electrolyte changes were <0.1% in patients who used several low-volume bowel preparations, which was not significantly different from patients using high-volume alternatives. However, the severe AEs that occur only rarely, are often reported in post-marketing surveillance data in case-series or retrospective studies. For some of the more recently developed bowel preparation fluids, such as NER1006, these data are still limited. Additionally, study populations of included studies in this meta-analysis mostly comprised healthy adult patients, excluding patients at risk for AEs or unable to drink larger volumes. This should be taken into account when deciding on the most suitable laxative for a particular patient.

Bowel preparation quality can be improved in several ways. On the one hand, lowering the volume of bowel preparation fluids may reduce non-compliance rates in patients. On the other hand, diet restrictions may influence the experienced burden of bowel preparation significantly. Compared to a clear liquid diet (CLD), low-residue diets (LRD) are better tolerated. Two meta-analyses compared LRD to CLD in studies with similar bowel preparation solutions in both arms and found an equal bowel cleansing efficacy but better tolerability with a higher willingness to repeat for LRD. Furthermore, too many rules and restrictions for patients can be overwhelming and may undermine understanding the importance of adequate cleansing. Enhanced patient education has been shown to improve compliance with bowel preparation regimens.

As percentage (intention-to-treat)

| Overall Bias | Selection of the reported result | Measurement of the outcome | Mising outcome data | Deviations from intended interventions | Randomization process |
|--------------|---------------------------------|---------------------------|--------------------|---------------------------------------|----------------------|
| Low risk     | Some concerns                   | Low risk                  | Low risk           | Low risk                              | High risk            |

Figure 7 Summary of risk of bias for fluid studies (Cochrane RoB2 tool). The Cochrane RoB2 tool assesses the risk of bias across five domains, including randomization process, protocol deviations, missing data, outcome measurement, and selection of the reported result. The overall risk of bias is determined by the highest risk within the subdomains. This figure summarizes the risk of bias within all included studies, as percentage of the total number of studies.
to improve colonoscopy preparation,97 for example using visual aids or mobile apps in addition to regular counseling.97–99 Two meta-analyses concluded that enhanced instructions benefit bowel preparation quality and ADR.100,101 although another meta-analysis acknowledging these benefits, pointed to a possible risk of publication bias.102

An interesting and possibly useful development may be the use of bowel cleansing devices. Using mechanical bowel cleansing before or during colonoscopy is proposed as an alternative to oral laxatives in selected patient groups.103–107 Preprocedural devices work through retrograde bowel lavage using pressurized water one hour before colonoscopy,108–110 while intraprocedural devices can be used during colonoscopy providing water-pressured cleansing.107,111–113 Feasibility studies have shown a clear potential, with adequate bowel preparation achieved in 97.9–100% and 68.8–91.1% of patients in whom intraprocedural devices107,111–113 or preprocedural devices,108–110 respectively, were used. Nonetheless, the use of intraprocedural devices adds significantly to the total procedure time, and preprocedural devices require a specialized nurse to operate the system. The associated costs may prohibit ubiquitous use, but the application of these bowel cleansing devices could be of interest in patients with risk factors for inadequate preparation, in whom a repeat endoscopic procedure often is indicated. Additionally, these devices could reduce admission time for inpatients.

**Strengths and limitations**

The strengths of our meta-analysis are the large number of patients included (n = 13,222) and the robustness of the results in the extensive sensitivity analysis. Moreover, we only included studies in which bowel preparation fluids with a volume of ≤1 L were included. Currently, 2L-PEGA is widely prescribed and recommended,1 but some patients still have difficulty with this volume. This makes ≤1 L fluids a welcome innovation.

The large heterogeneity in our meta-analysis inevitably limits interpretation of the results. This is illustrated by the reduced efficacy of 1L-PEGA after removing outliers and studies with a high risk of bias. Pooling the proportion of adequately prepped patients might have introduced heterogeneity in our results, besides the existing heterogeneity due to different study locations (Asia, Europe), dietary instructions, dosing regimens, and use of additives. Through subgroup and extensive sensitivity analyses, the influence of this heterogeneity could be minimized, and this further endorsed the robustness of our results. Although we could not take into account individual patients’ risk factors for poor bowel preparation, such as high age, body mass index, history of poor preparation, constipation, or history of neurological disorders,9,17,114 the RCTs in this meta-analysis frequently did not include patients who, for example, had serious systemic illnesses or used tricyclic antidepressants. While the use of different bowel preparation scales across studies is a drawback for performing a meta-analysis, our approach is not different from other published meta-analyses.90,115 The trend that a large proportion of published studies are non-inferiority trials and underpowered to detect superiority, and the great variety of comparative arms led us to only pool the efficacy of the ultra-low volume fluids without the comparative high-volume arms of the included studies. This enabled us to select more studies, giving a more precise direction to the pooled effect.

**CONCLUSION**

Large scale use of ultra-low volume bowel preparation is limited by an overall efficacy of these ≤1 L fluids below the 90% ESGE quality target. Therefore, their use might mainly be considered in selected patient populations with no risk factors for dehydration-related complications or inadequate preparation, as well as for patients having difficulty drinking large volumes.

**ACKNOWLEDGMENTS**

We thank Dr O.Y. Chan for assistance in performing the systematic search and Dr R. Akkersmans for statistical advice.

**CONFLICT OF INTEREST**

Author P.S. receives unrestricted grants from Pentax (Japan), Norgine (UK), Motus GI (USA), MicroTech (China) and The eNose Company (Netherlands) and is in the advisory board of Motus GI (USA) and Boston Scientific (USA). Authors MvR and KvK declare no conflict of interest for this article.

**FUNDING INFORMATION**

None.

**REFERENCES**

1 Hassan C, East J, Radaelli F et al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. Endoscopy 2019; 51: 775–94.
2 Saltzman JR, Cash BD, Pasha SF et al. Bowel preparation before colonoscopy. Gastrointest Endosc 2015; 81: 781–94.
3 Johnson DA, Barkun AN, Cohen LB et al. Optimizing adequacy of bowel cleansing for colonoscopy: Recommendations from the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2014; 109: 1528–45.
4 Harewood GC, Sharma VK, de Garmo P. Impact of colonoscopy preparation quality on detection of suspected colonic neoplasia. Gastrointest Endosc 2003; 58: 76–9.
5 Froehlich F, Wietlisbach V, Govers JJ, Burnand B, Vader JP. Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: The European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study. Gastrointest Endosc 2005; 61: 378–84.
6 Rex DK, Imperiale TF, Latinovich DR, Bratcher LL. Impact of bowel preparation on efficiency and cost of colonoscopy. Am J Gastroenterol 2002; 97: 1696–700.
7 Kingsley J, Karanth S, Revere FL, Agrawal D. Cost effectiveness of screening colonoscopy depends on adequate bowel preparation rates - A modeling study. PLoS One 2016; 11: e0167452.
8 Hassan C, Brethauer M, Kaminski MF et al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy 2013; 45: 142–50.
9 Dik VK, Moons LM, Huyuk M et al. Predicting inadequate bowel preparation for colonoscopy in participants receiving split-dose bowel preparation: Development and validation of a prediction score. Gastrointest Endosc 2015; 81: 665–72.
10 Gandhi K, Tofani C, Sokach C, Patel D, Kastenberg D, Daskalakis C. Patient characteristics associated with quality of colonoscopy preparation: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018; 16: 357–69.e10.
11 Sharara AI, El Reda ZD, Harb AH et al. The burden of bowel preparations in patients undergoing elective colonoscopy. United Eur Gastroenterol J 2016; 4: 314–8.
12 McLachlan SA, Clements A, Austoker J. Patients’ experiences and reported barriers to colonoscopy in the screening context—A systematic review of the literature. Patient Educ Couns 2012; 86: 137–46.
13 Fordtran JS, Hofmann AF. Seventy years of polyethylene glycols in gastrointestinalology: The Journey of PEG 4000 and 3350 from nonabsorbable marker to colonoscopy preparation to osmotic laxative. Gastroenterology 2017; 152: 675–80.
14 Xie Q, Chen L, Zhao F et al. A meta-analysis of randomized controlled trials of low-volume polyethylene glycol plus ascorbic acid versus standard-volume polyethylene glycol solution as bowel preparations for colonoscopy. PLoS One 2014; 9: e99092.
15 Jin Z, Lu Y, Zhou Y, Gong B. Systematic review and meta-analysis: Sodium picosulfate/magnesium citrate vs. polyethylene glycol for colonoscopy preparation. Eur J Clin Pharmacol 2016; 72: 523–32.
16 Seo SI, Kang JG, Kim HS, Jang MK, Kim HY, Shin WG. Efficacy and tolerability of 2-L polyethylene glycol with ascorbic acid versus sodium picosulfate with magnesium citrate: A randomized controlled trial. Int J Colorectal Dis 2018; 33: 541–8.
17 Hassan C, Fuccio L, Bruno M et al. A predictive model identifies patients most likely to have inadequate bowel preparation for colonoscopy. Clin Gastroenterol Hepatol 2012; 10: 501–6.
18 Waldmann E, Penz D, Majcher B et al. Impact of high-volume, intermediate-volume and low-volume bowel preparation on colonoscopy quality and patient satisfaction: An observational study. United Eur Gastroenterol J 2019; 7: 114–24.
19 Ouizzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—A web and mobile app for systematic reviews. Syst Rev 2016; 5: 210.
20 Kastenberg D, Bertiger G, Brogadir S. Bowel preparation quality scales for colonoscopy. World J Gastroenterol 2018; 24: 2833–43.
21 Rostom A, Jolicoeur E. Validation of a new scale for the assessment of bowel preparation quality. Gastrointest Endosc 2004; 59: 482–6.
22 Lai EJ, Calderwood AH, Doros G, Fix OK, Jacobson BC. The Boston bowel preparation scale: A valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc 2009; 69: 620–5.
23 Veroniki AA, Jackson D, Viechtbauer W et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods 2016; 7: 55–79.
24 Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat 1950; 21: 607–11.
25 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–58.
26 Viechtbauer W, Cheung MWL. Outlier and influence diagnostics for meta-analysis. Res Synth Methods 2010; 1: 112–25.
27 Bajtaj B, Mahé C, Pignon JP, Hill C. A graphical method for exploring heterogeneity in meta-analyses: Application to a meta-analysis of 65 trials. Stat Med 2002; 21: 2641–52.
28 Oklin I, Dahabreh IJ, Trikalinos TA. GOSH—a graphical display of study heterogeneity. Res Synth Methods 2012; 3: 214–23.
29 R Core Team. A language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2012. https://www.R-project.org, 2019.
30 Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: A practical tutorial. Evid Based Ment Health 2019; 22: 153–60.
31 Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36: 1–48.
32 Harrer M, Cuijpers P, Furukawa T, Ebert D. dmnetar: Companion R Package For The Guide “Doing Meta-Analysis in R”. R package version 0.0. 9000, 2019.
33 Sterne JAC, Savović J, Page MJ et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: 14898.

© 2021 The Authors. Digestive Endoscopy published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.
34. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009; 339: b2535.

35. Choi HS, Chung JW, Lee JW et al. Polyethylene glycol plus ascorbic acid is as effective as sodium picosulfate with magnesium citrate for bowel preparation: A randomized trial. J Dig Dis 2016; 17: 268–73.

36. Dwyer JP, Tan JYC, Paul E et al. White Diet with split-dose Picosalax is preferred, better tolerated, and non-inferior to day-before clear fluids with polyethylene glycol plus sodium picosulfate-magnesium citrate for morning colonoscopy: A randomized, non-inferiority trial. JGH Open 2017; 1: 38–43.

37. Gweon TG, Kim SW, Noh YS et al. Prospective, randomized comparison of same-day dose of 2 different bowel cleanser for afternoon colonoscopy. Medicine (Baltimore) 2015; 94: e628.

38. Heetun Z, Crowley R, Zeb F et al. Comparison of polyethylene glycol vs sodium picosulphate vs sodium biphosphonate by efficacy in bowel cleansing and patients’ tolerability: A randomized trial. Ir J Med Sci 2016; 185: 629–33.

39. Hookey L, Bertiger G, Lee Johnson K, Seifu Y, Brogardir SP. Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: A randomized, controlled, non-inferiority trial. Therap Adv Gastroenterol 2019; 12: 175628419851510.

40. Hung SY, Chen HC, Chen WT. A randomized trial comparing the bowel cleansing efficacy of sodium picosulfate/magnesium citrate and polyethylene glycol/bisacodyl (The Bowklean Study). Sci Rep 2020; 10: 5604.

41. Jun JH, Han KH, Park JK et al. Randomized clinical trial comparing fixed-time split dosing and split dosing of oral Picosulfate regimen for bowel preparation. World J Gastroenterol 2017; 23: 5986–93.

42. Kiesslich R, Schubert S, Mross M et al. Efficacy and safety of PICOPREP tailored dosing compared with PICOPREP day-before dosing for colon cleansing: A multi-centric randomised study. Endosc Int Open 2017; 5: E282–90.

43. Kim HG, Huh KC, Koo HS et al. Sodium picosulfate with magnesium citrate (SPMC) plus laxative is a good alternative to conventional large volume polyethylene glycol in bowel preparation: A multicentered randomized single-blinded trial. Gut Liver 2015; 9: 494–501.

44. Kim MJ, Hong CW, Kim BC et al. Phase II randomized controlled trial of combined oral laxatives medication for Bowel PREparation (COMBO-PREP) study. Medicine 2016; 95: e2824.

45. Klare P, Poloschek A, Walter B et al. Single-day sodium picosulfate and magnesium citrate versus split-dose polyethylene glycol for bowel cleansing prior to colonoscopy: A prospective randomized endoscopist-blinded trial. J Gastroenterol Hepatol 2015; 30: 1627–34.

46. Kojeczy V, Matous J, Keil R et al. A head-to-head comparison of 4-L polyethylene glycol and low-volume solutions before colonoscopy: Which is the best? A multicentre, randomized trial. Int J Colorectal Dis 2017; 32: 1763–6.

47. Kojecky V, Matous J, Keil R et al. The optimal bowel preparation intervals before colonoscopy: A randomized study comparing polyethylene glycol and low-volume solutions. Dig Liver Dis 2018; 50: 271–6.

48. Munsterman ID, Cleeren E, van der Ploeg T, Brochet R, van der Hulst R. ‘Pico-Bello-Klean study’: Effectiveness and patient tolerability of bowel preparation agents sodium picosulphate-magnesium citrate and polyethylene glycol before colonoscopy. A single-blinded randomized trial. Eur J Gastroenterol Hepatol 2015; 27: 29–38.

49. Munoz-Navas M, Calleja JL, Payera G et al. A randomized trial to compare the efficacy and tolerability of sodium picosulfate-magnesium citrate solution vs. 4 L polyethylene glycol solution as a bowel preparation for colonoscopy. Int J Colorectal Dis 2015; 30: 1407–16.

50. Pisera M, Franczyc R, Wieszczcy P et al. The impact of low-versus standard-volume bowel preparation on participation in primary screening colonoscopy: A randomized health services study. Endoscopy 2019; 51: 227–36.

51. Pohl J, Halphen M, Kleoss HR, Fischbach W. Impact of the quality of bowel cleansing on the efficacy of colonic cancer screening: A prospective, randomized, blinded study. PLoS One 2015; 10: e0126067.

52. Prieto-Frias C, Munoz-Navas M, Betes MT et al. Split-dose sodium picosulfate-magnesium citrate colonoscopy preparation achieves lower residual gastric volume with higher cleansing effectiveness than a previous-day regimen. Gastrointest Endosc 2016; 83: 566–73.

53. Rostom A, Dube C, Bishay K, Antonova L, Heitman SJ, Hilsden R. A randomized clinical prospective trial comparing split-dose picosulfate/magnesium citrate and polyethylene glycol for colonoscopy preparation. PLoS One 2019; 14: e0211136.

54. Sahebally SM, Burke JP, Chu S, Mabadeje O, Geoghegan J. A randomized controlled trial comparing polyethylene glycol + ascorbic acid with sodium picosulphate + magnesium citrate solution for bowel cleansing prior to colonoscopy. Ir J Med Sci 2014; 184: 819–23.

55. Schulz C, Muller J, Sauter J et al. Superiority of a split-dose regimen of sodium picosulfate/magnesium citrate (SPMC) in comparison to a prior-day schedule (AM/PM) for colonoscopy preparation. A randomized single-blinded study. J Gastrointest Liver Dis 2020; 25: 295–302.

56. Voissou T, Tantau A, Voissou A et al. Preparation regimen is more important than patient-related factors: A randomized trial comparing a standard bowel preparation before colonoscopy with an individualized approach. Rom J Intern Med 2017; 55: 36–43.

57. Yoo IK, Lee JS, Chun HJ et al. A randomized, prospective trial on efficacy and tolerability of low-volume bowel preparation methods for colonoscopy. Dig Liver Dis 2015; 47: 131–7.
58 Schreiber S, Baumgart DC, Dreenth JPH et al. Colon cleansing efficacy and safety with 1 L NER1006 versus sodium picosulfate with magnesium citrate: A randomized phase 3 trial. Endoscopy 2019; 51: 73–84.

59 Kim SH, Kim JH, Keum B et al. A randomized, endoscopist-blinded, prospective trial to compare the efficacy and patient tolerability between bowel preparation protocols using sodium picosulfate magnesium citrate and polyethylene glycol (1 L and 2 L) for colonoscopy. Gastroenterol Res Pract 2020; 2020: 9548171.

60 Bisschops R, Manning J, Clayton LB, Ng Kvet Shing R, Alvarez-Gonzalez M. Colon cleansing efficacy and safety with 1 L NER1006 versus 2 L polyethylene glycol + ascorbate: A randomized phase 3 trial. Endoscopy 2019; 51: 60–72.

61 DeMicco MP, Clayton LB, Pilot J, Epstein MS. Novel 1 L polyethylene glycol-based bowel preparation NER1006 for overall and right-sided colon cleansing: A randomized controlled phase 3 trial versus trisulfate. Gastrointest Endosc 2018; 87: 677–87.e3.

62 Choi SJ, Kim ES, Choi BK et al. A randomized controlled trial comparing the efficacy of 1-L polyethylene glycol solution with ascorbic acid plus prucalopride versus 2-L polyethylene glycol solution with ascorbic acid for bowel preparation. Scand J Gastroenterol 2018; 53: 1619–24.

63 Kamei M, Shibuya T, Takahashi M et al. Efficacy and acceptability of 1 liter of polyethylene glycol with ascorbic acid vs. 2 liters of polyethylene glycol plus mosapride and sennoside for colonoscopy preparation. Med Sci Monit 2018; 24: 523–30.

64 Kang SH, Jeen YT, Lee JH et al. Comparison of a split-dose bowel preparation with 2 liters of polyethylene glycol plus ascorbic acid and 1 liter of polyethylene glycol plus ascorbic acid and bisacodyl before colonoscopy. Gastrointest Endosc 2017; 86: 343–8.

65 Kim SH, Kim ER, Kim K et al. Combination of bisacodyl suppository and 1 L polyethylene glycol plus ascorbic acid is a non-inferior and comfortable regimen compared to 2 L polyethylene glycol plus ascorbic acid. Dig Endosc 2020; 32: 600–7.

66 Kwon JE, Lee JW, Im JP et al. Comparable efficacy of a 1-L PEG and ascorbic acid solution administered with bisacodyl versus a 2-L PEG and ascorbic acid solution for colonoscopy preparation: A prospective, randomized and investigator-blinded trial. PLoS One 2016; 11: e0162051.

67 Banerjee R, Chaudhari H, Shah N, Saravanan A, Manu T, Reddy DN. Addition of Lubiprostone to polyethylene glycol (PEG) enhances the quality & efficacy of colonoscopy preparation: A randomized, double-blind, placebo controlled trial. BMC Gastroenterol 2016; 16: 133.

68 Tian X, Shi B, Liu XL, Chen H, Chen WQ. A randomized trial of split dose 3 L polyethylene glycol lavage solution, 2 L polyethylene glycol lavage combined with castor oil, and 1 L of polyethylene glycol lavage solution combined with castor oil and ascorbic acid for preparation for colonoscopy. Front Med (Lausanne) 2019; 6: 158.

69 Yang HJ, Park DI, Park SK et al. Novel sulfate tablet PBK-1701TC versus oral sulfate solution for colon cleansing: A randomized phase 3 trial. J Gastroenterol Hepatol 2020; 35: 29–36.

70 Lee HH, Lim CH, Kim JS et al. Comparison between an oral sulfate solution and a 2 L of polyethylene glycol+ascorbic acid as a split dose bowel preparation for colonoscopy. J Clin Gastroenterol 2019; 53: e431–7.

71 Gerard DP, Foster DB, Holden JL, Kang J, Raiser MW. Clinical trial of 1000 subjects randomized to 5 low-volume bowel preparations for colonoscopy and their acceptance of split-dose bowel preparations. J Clin Gastroenterol 2017; 51: 512–21.

72 Poyrazoglu OK, Yalniz M. Two low-dose bowel-cleansing regimens: Efficacy and safety of senna and sodium phosphate solution for colonoscopy. Patient Prefer Adherence 2015; 9: 1325–31.

73 Hung JS, Yi CH, Liu TT, Lei WY, Wong MW, Chen CL. Does prucalopride reduce the dose of sodium phosphate in bowel preparation? A single-blind, randomized, and prospective study. J Dig Dis 2019; 20: 294–300.

74 Kang JW, Chuang CH, Chen CY et al. Different schedules of bowel preparation with sodium phosphate lead to different bowel cleansing effects and adenoma detection rates at colonoscopy. Adv Dig Med 2015; 2: 12–7.

75 Khorasanynejad R, Norouzi A, Roshandel G, Besharat S. Bowel preparation for a better colonoscopy using polyethylene glycol or C-lax: A double blind randomized clinical trial. Middle East J Dig Dis 2017; 9: 212–7.

76 Thuikral C, Tewani SK, Lake AJ et al. Results of a community-based, randomized study comparing a clear liquid diet with a low-residue diet using a magnesium citrate preparation for screening and surveillance colonoscopies. J Clin Gastroenterol 2019; 53: 34–9.

77 Millien VO, Mansour NM. Bowel preparation for colonoscopy in 2020: A look at the past, present, and future. Curr Gastroenterol Rep 2020; 22: 28.

78 Martel M, Barkun AN, Menard C, Restellini S, Kherad O, Vanasse A. Split-dose preparations are superior to day-before bowel cleansing regimens: A meta-analysis. Gastroenterology 2015; 149: 79–88.

79 Enestvedt BK, Tofani C, Laine LA, Tierney A, Fennerty MB. Sodium phosphate bowel preparations, based on systematic review and meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 1225–31.

80 Spadaccini M, Frazzoni L, Vanella G et al. Efficacy and tolerability of high- vs low-volume split-dose bowel cleansing regimens for colonoscopy: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2020; 18: 1454–65.

81 Rocha RSP, Ribeiro IB, de Moura DTH et al. Sodium picosulphate or polyethylene glycol before elective colonoscopy in outpatients? A systematic review and meta-analysis. World J Gastrointest Endosc 2018; 10: 422–41.

82 Yi LJ, Tian X, Shi B et al. Low-volume polyethylene glycol improved patient attendance in bowel preparation before...
colonoscopy: A meta-analysis with trial sequential analysis. *Front Med (Lausanne)* 2019; 6: 92.
83 Seo EH, Kim TO, Park MJ et al. Optimal preparation-to-colonoscopy interval in split-dose PEG bowel preparation determines satisfactory bowel preparation quality: An observational prospective study. *Gastrointest Endosc* 2012; 75: 583–90.
84 Zawaly K, Rumbolt C, Abou-Setta AM et al. The efficacy of split-dose bowel preparations for polyp detection: A systematic review and meta-analysis. *Am J Gastroenterol* 2019; 114: 884–92.
85 Ko SH, Lim CH, Kim JY, Kang SH, Baeg MK, Oh HJ. Case report on a case of acute phosphate nephropathy following oral sodium phosphate bowel purgative: An underrecognized cause of chronic renal failure. *J Am Soc Nephrol* 2016; 27: 249–55.
86 Markowitz GS, Stokes MB, Radhakrishnan J, D’Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: An underrecognized cause of chronic renal failure. *J Am Soc Nephrol* 2005; 16: 3389–96.
87 Mathus-Vliegen EMH, van der Vliet K, Wignand-van der Storm IJ, Stadwijk JS. Split-dose bowel cleansing with picosulphate is safe and better tolerated than 2 L polyethylene glycol bowel preparation. *World J Gastroenterol* 2014; 20: 12350–4.
88 Onishi S, Yoshino S. Cathartic-induced fatal hypermagnesemia in the elderly. *Intern Med* 2006; 45: 207–10.
89 Ko SH, Lim CH, Kim JY, Kang SH, Baeg MK, Oh HJ. Case report on a case of acute phosphate nephropathy following oral sodium phosphate bowel purgative: An underrecognized cause of chronic renal failure. *J Am Soc Nephrol* 2005; 16: 3389–96.
90 Mathus-Vliegen EMH, van der Vliet K, Wignand-van der Storm IJ, Stadwijk JS. Split-dose bowel cleansing with picosulphate is safe and better tolerated than 2 L polyethylene glycol bowel preparation. *World J Gastroenterol* 2014; 20: 12350–4.
91 Lee SP, Park E, Kim HV et al. Does 2 L polyethylene glycol plus ascorbic acid increase the risk of renal impairment compared to 4 L polyethylene glycol? *Dig Dis Sci* 2016; 61: 3207–14.
92 Sacks NC, Sharma A, Cyr PL, Bertiger G, Dahdal DN, Brogadir SP. Real-world comparison of the effectiveness and safety of different bowel preparation agents. *Clin Exp Gastroenterol* 2018; 11: 289–99.
93 Alvarez-Gonzalez MA, Panteleon MA, Flores-Le Roux JA et al. Randomized clinical trial: A normocaloric low-fiber diet the day before colonoscopy is the most effective approach to bowel preparation in colorectal cancer screening colonoscopy. *Dis Colon Rectum* 2019; 62: 491–7.
94 Nguyen DL, Jamal MM, Nguyen ET, Puli SR, Bechtold ML. Low-residue versus clear liquid diet before colonoscopy: A meta-analysis of randomized, controlled trials. *Gastrointest Endosc* 2016; 83: 499–507.e1.
95 Avalos DJ, Sussman DA, Lara LF, Sarkis FS, Castro FJ. Effect of diet liberalization on bowel preparation. *South Med J* 2017; 110: 399–407.
96 Rutherford CC, Calderwood AH. Update on bowel preparation for colonoscopy. *Curr Treat Options Gastroenterol* 2018; 16: 165–81.
97 Serper M, Gawron AJ, Smith SG et al. Patient factors that affect quality of colonoscopy preparation. *Clin Gastroenterol Hepatol* 2014; 12: 451–7.
98 Liu Z, Zhang MM, Li YY, Li LX, Li YQ. Enhanced education for bowel preparation before colonoscopy: A state-of-the-art review. *J Dig Dis* 2017; 18: 84–91.
99 Walter B, Klare P, Strehe K et al. Improving the quality and acceptance of colonoscopy preparation by reinforced patient education with short message service: Results from a randomized, multicenter study (PERICLES-II). *Gastrointest Endosc* 2019; 89: 506–13.e4.
100 Guo X, Yang Z, Zhao L et al. Enhanced instructions improve the quality of bowel preparation for colonoscopy: A meta-analysis of randomized controlled trials. *Gastrointest Endosc* 2017; 85: 90–7.e6.
101 Tian X, Xu LL, Liu XL, Chen WQ. Enhanced patient education for colon polyp and adenoma detection: Meta-analysis of randomized controlled trials. *JMIR Mhealth Uhealth* 2020; 8: e17372.
102 Chang CW, Shih SC, Wang HY et al. Meta-analysis: The effect of patient education on bowel preparation for colonoscopy. *Endosc Int Open* 2015; 3: E646–52.
103 Parekh PJ, Oldfield EC, Johnson DA. Bowel preparation for colonoscopy: What is best and necessary for quality? *Curr Opin Gastroenterol* 2019; 35: 51–7.
104 Obstein KL, Valdastri P. Advanced endoscopic technologies for colorectal cancer screening. *World J Gastroenterol* 2013; 19: 431–9.
105 Rigaux J, Juriens I, Deviere J. A novel system for the improvement of colonoscopy cleaning during colonoscopy. *Endoscopy* 2012; 44: 703–6.
106 Eliakim R, Yassin K, Lachter J, Chowars Y. A novel device to improve colon cleanliness during colonoscopy. *Endoscopy* 2012; 44: 655–9.
107 van Keulen KE, Neumann H, Schattenberg JM et al. A novel device for intracolonoscopy cleansing of inadequately prepared colonoscopy patients: A feasibility study. *Endoscopy* 2019; 51: 85–92.
108 Kaiser Junior RL, de Quadros LG, Faria MAG, Kaiser FSL, Campo JCO, Zotarelli Filho IJ. Aquanet bowel cleansing device versus oral sodium picosulfate for pre-endoscopy bowel preparation: Propensity score analysis for interventional effectiveness evaluation. *Gastroenterol Res* 2018; 11: 18–24.
109 Kaiser-Junior RL, De-quadros LG, Flamini-junior M et al. New bowel preparation technique for colonoscopy: Clinical trial comparing aquanet and mannitol. *Arq Bras Cir Dig* 2018; 31: e1393.
110 Ayub K, Ketwaroo G, Abudayyeh S et al. Mechanical colon cleansing for screening colonoscopy: A randomized controlled trial. *J Dig Dis* 2017; 18: 691–7.

© 2021 The Authors. *Digestive Endoscopy* published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.
111 Perez Jimenez J, Diego Bermudez L, Gralnek IM, Martin Herrera L, Libes M. An intraprocedural endoscopic cleansing device for achieving adequate colon preparation in poorly prepped patients. J Clin Gastroenterol 2019; 53: 530–4.
112 Hoffman A, Murthy S, Pompetski L et al. Intraprocedural bowel cleansing with the JetPrep cleansing system improves adenoma detection. World J Gastroenterol 2015; 21: 8184.
113 Moshkowitz M, Fokra A, Itzhak Y, Arber N, Santo E. Feasibility study of minimal prepared hydroflush screening colonoscopy. United Eur Gastroenterol J 2016; 4: 105–9.
114 Gimeno-Garcia AZ, Baute JL, Hernandez G et al. Risk factors for inadequate bowel preparation: A validated predictive score. Endoscopy 2017; 49: 536–43.
115 Bucci C, Zingone F, Schettino P, Marmo C, Marmo R. Same-day regimen as an alternative to split preparation for colonoscopy: A systematic review with meta-analysis. Gastroenterol Res Pract 2019; 2019: 7476023.

SUPPORTING INFORMATION

ADDITIONAL SUPPORTING INFORMATION may be found in the online version of this article at the publisher’s web site.

Figure S1 Subgroup analysis based on additive use, sodium picosulfate/magnesium citrate (SPMC).
Figure S2 Subgroup analysis based on dosing schedule, sodium picosulfate/magnesium citrate (SPMC).
Figure S3 Subgroup analysis based on diet, sodium picosulfate/magnesium citrate (SPMC).
Figure S4 Pooled efficacy 1 L PEG with ascorbate (PEGA), additives subgroups.
Figure S5 Pooled efficacy of 1 L PEG with ascorbate (PEGA), dosing subgroups.
Figure S6 Pooled efficacy of 1 L PEG with ascorbate (PEGA), diet subgroups.
Figure S7 Leave-1-out analyses for pooled efficacy and heterogeneity.
Figure S8 Influence analyses and Baujat-plots for identifying outliers.
Figure S9 Graphic display of study heterogeneity (GOSH) plot analysis for identifying outliers, sodium picosulfate with magnesium citrate (SPMC).
Figure S10 Graphic display of study heterogeneity (GOSH) plot analysis for identifying outliers, 1 L PEG with ascorbate.
Figure S11 Funnel plots of percentage adequately prepped patients per fluid.
Figure S12 Traffic light plot for individual risk of bias of included studies, Cochrane RoB2 tool.
Appendix S1 Background information bowel preparation fluids.
Appendix S2 Search strategy 17 April 2020.
Appendix S3 Subgroup and heterogeneity analyses (figures).